Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc G Berger

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|July 5, 2019
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndromeMarc G Berger, Bruno Pereira, Philippe Rousselot, et al.
Scientific Reports|March 18, 2021
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34<sup>-</sup> and immature CD34<sup>+</sup> cellsMarc G Berger, Benjamin Lebecque, Thomas Tassin, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|August 30, 2012
Measurement of imatinib uptake by flow cytometryCéline Bourgne, Mahchid Bamdad, Alexandre Janel, et al.
Clinical Pharmacokinetics|August 22, 2018
Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1Juliette Berger, Marie Vigan, Bruno Pereira, et al.
Journal of Inherited Metabolic Disease|March 20, 2025
Never-Treated, Non Splenectomised Patients With Gaucher Disease (The French GANT Study): The Prospective Follow-UpAlberto Nasce, Yann Nguyen, Nadia Belmatoug, et al.
Leukemia|August 1, 2025
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific toolsSylvain Moinard, Benjamin Lebecque, Tom Lachaise, et al.
Orphanet Journal of Rare Diseases|October 28, 2025
French national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher diseaseFabrice Camou, Christine Serratrice, Magali Pettazzoni, et al.
Orphanet Journal of Rare Diseases|October 11, 2012
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patientsJérôme Stirnemann, Marie Vigan, Dalil Hamroun, et al.
Leukemia|July 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI TrialFabio Efficace, Francois-Xavier Mahon, Johan Richter, et al.
Orphanet Journal of Rare Diseases|February 14, 2026
Impact of COVID-19 infection in patients with inherited metabolic diseases: a National Multicenter Study from the French IMDs Healthcare Network for Rare DiseasesClaire Douillard, Aurélia Poujois, Nadia Belmatoug, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|July 5, 2019
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndromeMarc G Berger, Bruno Pereira, Philippe Rousselot, et al.
Scientific Reports|March 18, 2021
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34<sup>-</sup> and immature CD34<sup>+</sup> cellsMarc G Berger, Benjamin Lebecque, Thomas Tassin, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|August 30, 2012
Measurement of imatinib uptake by flow cytometryCéline Bourgne, Mahchid Bamdad, Alexandre Janel, et al.
Clinical Pharmacokinetics|August 22, 2018
Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1Juliette Berger, Marie Vigan, Bruno Pereira, et al.
Journal of Inherited Metabolic Disease|March 20, 2025
Never-Treated, Non Splenectomised Patients With Gaucher Disease (The French GANT Study): The Prospective Follow-UpAlberto Nasce, Yann Nguyen, Nadia Belmatoug, et al.
Leukemia|August 1, 2025
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific toolsSylvain Moinard, Benjamin Lebecque, Tom Lachaise, et al.
Orphanet Journal of Rare Diseases|October 28, 2025
French national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher diseaseFabrice Camou, Christine Serratrice, Magali Pettazzoni, et al.
Orphanet Journal of Rare Diseases|October 11, 2012
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patientsJérôme Stirnemann, Marie Vigan, Dalil Hamroun, et al.
Leukemia|July 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI TrialFabio Efficace, Francois-Xavier Mahon, Johan Richter, et al.
Orphanet Journal of Rare Diseases|February 14, 2026
Impact of COVID-19 infection in patients with inherited metabolic diseases: a National Multicenter Study from the French IMDs Healthcare Network for Rare DiseasesClaire Douillard, Aurélia Poujois, Nadia Belmatoug, et al.
Pageof 6